Skip to main content
OpenTrials
Completed

NCT Number: NCT02338739

An Adaptive Strategy for Preventing and Treating Lapses of Retention in Adult HIV Care (AdaPT-R) in Nyanza, Kenya

Retaining HIV-infected patients in care is critical, but loss to follow-up after enrolment often reaches 20%-40% by two years, placing millions of patients at risk of poor outcomes. A strategy to optimize retention within resource constraints is urgently needed. Sequential adaptive strategies - a novel class of public health approaches - may offer a solution. A candidate sequential adaptive strategy would start with a less expensive intervention (e.g., SMS) in all patients and then apply a more costly and intensive one (e.g., navigator) only to patients who show early signs of poor retention. This study involves a sequential multiple assignment randomized trial to evaluate a family of such strategies. the investigators will randomize 1,800 adults newly initiating antiretroviral treatment (ART) at 4 HIV clinics in the Nyanza region of Kenya to (1) standard of care routine education and counselling (REC), (2) SMS text messages, or (3) transport vouchers. Patients with early signs of weakening retention (defined as the first time a patient is 14 days late for an appointment) will be re-randomized to (1) a single episode of outreach (standard of care), (2) SMS combined with vouchers, or (3) a peer navigator. Patients not successfully contacted by 28 days after missed visit (and not verified to have left the area or transferred to another clinic) will also be rerandomized to of one the same three re-engagement interventions. Individuals randomized at first stage to SMS or voucher that do not miss a visit by at least 14 days in the first 12 months of follow up will be re-randomized at 12 months to stop first stage intervention or continue with that same intervention to 24 months. The investigators primary objective is to assess the comparative effectiveness of sequenced intervention strategies to prevent initial lapses in retention and to treat those that occur. The investigators primary endpoint is fraction of time retained in care two years after enrolment. In addition, the investigators will assess the comparative effectiveness of first-stage strategies (REC, SMS, voucher) to prevent lapses in retention, and the comparative effectiveness of second stage strategies (outreach, SMS + voucher, navigator) to re-engage patients after initial lapse. This study will also compare outcomes among patients who continue versus discontinue the SMS and voucher interventions, including a small complementarity component utilizing qualitative methods to examine the voucher approach and the effects of discontinuing this approach after success among a subset of participants. At study conclusion the investigators output will be a menu of adaptive strategies for retention, accompanied by estimates of cost and effectiveness, which policy makers in different settings can use to advance the impact of HIV care and treatment programs in Africa.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kenya Medical Research Institute

Kisumu, Nyanza, Kenya

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV-infection
  • 18 years old
  • Planning to remain in the study area (Nyanza region) for the duration of the study, capable of informed consent
  • Newly initiating ART (within past 90 days)
  • Access to a cell phone
  • Ability to read or be read SMS messages
  • And willingness to be contacted by clinic upon missed appointment.

Exclusion criteria

  • Plans to move out of Nyanza region or acutely ill and requiring hospitalization.
  • Hospitalized patients who later recover will be eligible for enrolment at the first post-hospitalization clinic visit during which eligibility criteria are met.
  • No access to a cell phone.
  • Involvement in studies with the potential to influence retention behaviors.

Treatment and study plan

REC; Outreach if Failure

Behavioral

Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.

REC; SMS + Voucher if Failure

Behavioral

Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.

REC; Navigator if Failure

Behavioral

REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit

SMS; Outreach if Failure

Behavioral

SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit

SMS; Outreach if Failure; Stop SMS if Success

Behavioral

SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late

SMS; SMS+Voucher if Failure

Behavioral

SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.

SMS; SMS+Voucher if Failure; Stop SMS if Success

Behavioral

SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late

SMS; Navigator if Failure

Behavioral

SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit

SMS; Navigator if Failure; Stop SMS if Success

Behavioral

SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late

Voucher; Outreach if Failure

Behavioral

Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit

Voucher; Outreach if Failure; Stop Voucher if Success

Behavioral

Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late

Voucher; SMS+Voucher if Failure

Behavioral

Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit

Voucher; SMS+Voucher if Failure; Stop Voucher if Success

Behavioral

Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late

Voucher; Navigator if Failure

Behavioral

Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit

Voucher; Navigator if Failure; Stop Voucher if Success

Behavioral

Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late

Primary outcomes

  1. Retention

    Time frame: Up to two years after enrollment

    Fraction of time in care

Secondary outcomes

  1. Alive with suppressed HIV RNA level (<400 copies/ml)

    Time frame: Two years after study enrollment

    Number of subjects alive with suppressed HIV RNA levels (<400 copies/ml)

  2. Time from second randomization to return to clinic after initial retention lapse

    Time frame: Up to two years after enrollment

    Time from second randomization to re-engagement; re-engagement is defined as first visit back to clinic

  3. Mean visit adherence (% visits made)

    Time frame: Two years after study enrollment

    Proportion of kept scheduled appointments (range=0-100%), with kept visits being those attended by the patient and with the denominator excluding canceled visits

  4. Retention

    Time frame: Two years after enrollment

    Fraction of time in care

  5. Fraction on-time pharmacy pick-ups for antiretroviral drugs

    Time frame: Two years after enrollment

    Proportion of prescriptions filled and picked up by participants to prescriptions written

  6. Cost effectiveness

    Time frame: After two years of enrollment

    Cost per failure (virological failure (HIV RNA>=400 copies/ml) or death averted

  7. Patient-reported barriers to engagement

    Time frame: At years one and two after study enrollment

    Self-reported by questionnaire

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Kenya Medical Research Institute
  • National Institute of Mental Health (NIMH)
  • University of California, Berkeley
  • University of Washington

Registry information

Official study title

An Adaptive Strategy for Preventing and Treating Lapses of Retention in Adult HIV Care (AdaPT-R)

Acronym: AdaPT-R

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Jan 14, 2015
Registry last updated
Mar 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.